Connetics Announces 2005 Analyst and Investor Day in New York City; Event to Be Webcast Live.PALO ALTO, Calif. -- Connetics Corporation (Nasdaq: CNCT CNCT Connect CNCT Certified Network Computer Technician ), a specialty pharmaceutical company that develops and commercializes dermatology products, today announced that it will host its Analyst and Investor Day on April 14, 2005 at The Mandarin Oriental Hotel in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . The event will be broadcast live over the Internet including presentation slides beginning at approximately 10:30 a.m. Eastern Time. Connetics management will review key updates on areas encompassing commercial activities, marketed products, product pipeline and financial highlights. In addition to presentations by management, the event will feature a presentation from a leading physician expert in the field of dermatology. Investment professionals interested in attending Connetics' 2005 Analyst and Investor Day in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , should contact Heather LeDue at 650-843-2863 or hledue@connetics.com. To access the presentations via the Internet, go to the investor relations Investor relations The process by which the corporation communicates with its investors. section of www.connetics.com. A replay of the event will be available for 30 days. About Connetics Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. Connetics has branded its proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate clobetasol propionate (klōbā´t  sol´ prō´pē ) Foam, 0.05%, Luxiq(R) (betamethasone betamethasone /be·ta·meth·a·sone/ (ba?tah-meth´ah-son) a synthetic glucocorticoid, the most active of the antiinflammatory steroids; used topically as the benzoate, dipropionate, or valerate salts as an antiinflammatory, topically or valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(TM) (clindamycin) Foam, 1%. Connetics is developing Velac(R) (a combination of 1% clindamycin and 0.025% tretinoin tretinoin /tret·i·noin/ (tret´i-noin?) the all-trans stereoisomer of retinoic acid, used as a topical keratolytic in the treatment of acne vulgaris and disorders of keratinization and administered orally in the treatment of acute ) Gel, for treating acne, and Desilux(TM) (desonide) VersaFoam-EF, 0.05% a low-potency topical steroid formulated to treat atopic dermatitis. Connetics' product formulations aim to improve the management of dermatological diseases and provide significant product differentiation. In Connetics' marketed products, these formulations have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit www.connetics.com. Press Release Code: (CNCT-G) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion